Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Institute to fund new melanoma trials co-ordinator

17 June 2015

Melanoma Research Institute to fund new melanoma trials co-ordinator at Auckland City Hospital

The Melanoma Research Institute of New Zealand today announced it will provide funding for a melanoma trials co-ordinator at Auckland City Hospital.

Once appointed, the new co-ordinator will work alongside Dr Rosalie Fisher and Dr Mike McCrystal on the Auckland District Health Board’s Cancer and Blood Service team.

Both doctors are welcoming the news of an extra set of hands, as it will boost the hospital’s capacity to hold vital trials for melanoma research.

“This is a very important step in increasing the capacity to undertake clinical trials in patients with melanoma,” said Dr Fisher. “I hope it will ultimately result in better survival rates of the Kiwis who are battling this devastating disease.”

Currently only two clinical trials are open to recruitment in New Zealand, but the Melanoma Research Institute is working to ensure there are more options available. Melanoma Research Institute director Dr Edward Watson said the new role is part of this push for greater access.

“The Institute has been working to increase access to clinical trials for New Zealanders suffering from advanced melanoma skin cancer and this new position will be a significant step forwards in achieving this aim,” Dr Watson said.

“We are enormously grateful to Mrs Paddy Carter, who has made this new role possible through her generous donation, which she made in remembrance of her husband Ron.”

Dr Watson said research is essential in order to combat melanoma in New Zealand, which has the highest incidence rate of anywhere in the world.

“The new treatments available today are a result of people participating in clinical trials in the past, so research is crucial,” Dr Watson said. “Taking part in a clinical trial also gives patients, especially those with advanced cancer, a chance to access new therapies that wouldn’t otherwise be available.”

The new trial co-ordinator will start at Auckland City Hospital on 1 July.


© Scoop Media

Business Headlines | Sci-Tech Headlines


By May 2018: Wider, Earlier Microbead Ban

The sale and manufacture of wash-off products containing plastic microbeads will be banned in New Zealand earlier than previously expected, Associate Environment Minister Scott Simpson announced today. More>>


Snail-ier Mail: NZ Post To Ditch FastPost

New Zealand Post customers will see a change to how they can send priority mail from 1 January 2018. The FastPost service will no longer be available from this date. More>>


Property Institute: English Backs Of Debt To Income Plan

Property Institute of New Zealand Chief Executive Ashley Church is applauding today’s decision, by Prime Minister Bill English, to take Debt-to-income ratios off the table as a tool available to the Reserve Bank. More>>


Divesting: NZ Super Fund Shifts Passive Equities To Low-Carbon

The NZ$35 billion NZ Super Fund’s NZ$14 billion global passive equity portfolio, 40% of the overall Fund, is now low-carbon, the Guardians of New Zealand Superannuation announced today. More>>


Split Decision - Appeal Planned: EPA Allows Taranaki Bight Seabed Mine

The Decision-making Committee, appointed by the Board of the Environmental Protection Authority to decide a marine consent application by Trans-Tasman Resources Ltd, has granted consent, subject to conditions, for the company to mine iron sands off the South Taranaki Bight. More>>